INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
1. Pomerantz LLP is investigating SMMT for potential securities fraud. 2. SMMT's stock fell 30.5% after disappointing trial results on ivonescimab. 3. The Phase III trial didn't show statistically significant overall survival improvements. 4. Investors are being contacted for potential class action participation. 5. Pomerantz has a history of successful securities litigation.